Connect Biopharma Shifts Focus to Rademikibart, Ends Pfizer Deal

Connect Biopharma Shifts Focus to Rademikibart, Ends Pfizer Deal

By
Alessio Bianchi
1 min read

Connect Biopharma is ending its licensing deal with Pfizer for an oral anti-inflammatory agent in order to prioritize its lead asset, rademikibart, a Phase 3-ready antibody candidate. The company's 2023 financials reflect a 27% decrease in near-term liquidity and long-term investments. Connect aims to engage in regulatory discussions in the U.S. and China regarding rademikibart's registrational programs in asthma and atopic dermatitis. Additionally, terminating the Pfizer deal is expected to extend Connect's cash runway and will result in a pause for their pre-clinical and discovery programs.

Key Takeaways

  • Connect Biopharma terminates licensing deal with Pfizer for CBP-174 to prioritize rademikibart.
  • Connect's 2023 financials show a 27% YoY drop in liquidity and investments.
  • Rademikibart, a Phase 3-ready antibody candidate, is up for regulatory discussions in the U.S. and China.
  • Termination of the Pfizer deal will extend Connect's cash runway, allowing it to pause pre-clinical and discovery programs.
  • Connect originally acquired rights to CBP-174 from Arena Pharmaceuticals before Pfizer's acquisition.

Analysis

Connect Biopharma's decision to end its licensing deal with Pfizer to prioritize its lead asset, rademikibart, is expected to have both short and long-term implications. In the short term, the company's 2023 financials reflect a 27% decrease in liquidity and long-term investments, impacting its operational capabilities. However, terminating the deal is predicted to extend Connect's cash runway, providing the flexibility to engage in regulatory discussions for rademikibart's registrational programs in asthma and atopic dermatitis. This move may affect Pfizer's strategic alliances, while also influencing investors' confidence in Connect Biopharma's future developments and its impact on the biopharmaceutical industry.

Did You Know?

  • Rademikibart, a Phase 3-ready antibody candidate, is up for regulatory discussions in the U.S. and China.
  • Connect's 2023 financials show a 27% YoY drop in liquidity and investments.
  • Termination of the Pfizer deal will extend Connect's cash runway, allowing it to pause pre-clinical and discovery programs.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings